EORTC Endocrine Task Force

Open studyStudy to be openClosed study
17761
Essai therapeutique d'immunothérapie active non spécifique après traitement à visée curative des epitheliomas de la langue mobile et du plancher buccal
1209
A phase II study exploring the safety and efficacy of BIBF1120 as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.

Back to Group-list